Get the Stockscreener App
1.33
3.10%
0.04
After Hours:
1.35
0.02
+1.50%
Tiziana Life Sciences Ltd stock is traded at $1.33, with a volume of 141.11K.
It is up +3.10% in the last 24 hours and up +9.02% over the past month.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.
See More
Previous Close:
$1.29
Open:
$1.29
24h Volume:
141.11K
Relative Volume:
0.70
Market Cap:
$169.24M
Revenue:
-
Net Income/Loss:
$-12.84M
P/E Ratio:
-11.64
EPS:
-0.1143
Net Cash Flow:
$-8.76M
1W Performance:
+4.72%
1M Performance:
+9.02%
6M Performance:
-36.97%
1Y Performance:
+64.20%
1-Day Range:
$1.27
$1.35
1-Week Range:
$1.14
$1.35
52-Week Range:
$0.7601
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Name
Tiziana Life Sciences Ltd
Sector
Industry
Phone
-
Address
-
Compare TLSA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.33 | 164.15M | 0 | -12.84M | -8.76M | -0.1143 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Dec-17-18 | Initiated | Laidlaw | Buy |
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Market movers: Tesla, Wells Fargo, Lucid Group, Tiziana Life Sciences, Trillion Energy… - Proactive financial news
Tiziana Life Sciences’ Intranasal Foralumab MSA Trial Highlighted in Late-Breaking Poster at 7th World Parkinson Congress - TipRanks
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress - The Manila Times
Tiziana Life Sciences (TLSA) highlights Phase 2a intranasal foralumab MSA trial at World Parkinson Congress - Stock Titan
Tiziana Life Sciences to present Phase 2a MSA study at World Parkinson Congress - Proactive financial news
Aug Setups: What is the Moat Score of BlackRock Virginia Municipal Bond Trust2026 Pullback Review & Stock Timing and Entry Methods - baoquankhu1.vn
Swing Trade: Can Tiziana Life Sciences Ltd maintain its current growth ratePortfolio Gains Report & Consistent Return Investment Signals - baoquankhu1.vn
Downgrade Watch: Is Tiziana Life Sciences Ltd a cyclical or defensive stockMarket Risk Analysis & Reliable Entry Point Alerts - baoquankhu1.vn
TLSA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Tiziana Life Sciences (NASDAQ:TLSA) Trading 6.8% HigherHere's What Happened - MarketBeat
Market movers: Nike, RH, Tiziana Life Sciences, Eli Lilly… - Proactive financial news
Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum - Benzinga
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging - Bitget
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging - Proactive financial news
Tiziana Life Sciences Reports Positive Preclinical Data for Nasal Anti-CD3 in Age-Related Cognitive Decline - TipRanks
Tiziana Life Sciences (NASDAQ: TLSA) posts positive nasal anti-CD3 data in aging model - Stock Titan
Tiziana Life Sciences Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging - marketscreener.com
Volume Report: What are the future prospects of Tiziana Life Sciences LtdInflation Watch & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Update Report: Does Tiziana Life Sciences Ltd outperform in volatile marketsQuarterly Trade Report & Risk Managed Investment Signals - baoquankhu1.vn
Aug Outlook: Does Tiziana Life Sciences Ltd offer margin of safety2026 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
If You Invested $1,000 in Tiziana Life Sciences Ltd Com (TLSA) - Stock Titan
Tiziana Life Sciences Ltd: Fundamental Analysis and Financial Ratings | 0RP | BMG889121031 - marketscreener.com
Macro Review: Is Tiziana Life Sciences Ltd stock a good dividend stock2026 Retail Activity & Verified Swing Trading Watchlists - baoquankhu1.vn
Large TLSA stake reported by director Gabriele M. Cerrone on Form 3 - Stock Titan
Macro Review: Is Tiziana Life Sciences Ltd subject to activist investor interest2026 Closing Moves & Weekly Sector Rotation Insights - baoquankhu1.vn
Forecast Cut: Can Tiziana Life Sciences Ltd maintain its current growth rate2026 Big Picture & Fast Moving Stock Watchlists - baoquankhu1.vn
Price Action: Can Tiziana Life Sciences Ltd be recession proofTrade Risk Report & High Accuracy Investment Signals - baoquankhu1.vn
TLSA Earnings History & Surprises | EPS & Revenue Results | TIZIANA LIFE SCIENCES LTD (NASDAQ:TLSA) - ChartMill
Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 4.4%Should You Sell? - MarketBeat
Tiziana Life Sciences (TLSA) Stock Analysis Report | Financials & Insights - Benzinga Japan
Whats next for Tiziana Life Sciences Ltd stockAnalyst Upgrade & Real-Time Volume Trigger Notifications - baoquankhu1.vn
New Highs: Can Tiziana Life Sciences Ltd expand its profit margins2026 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Aug Macro: Is Tiziana Life Sciences Ltd a stock for growth or value investorsMarket Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Day Trade: Can Tiziana Life Sciences Ltd maintain its current growth rate2025 Volume Leaders & Momentum Based Trading Ideas - baoquankhu1.vn
Market movers: Circle Internet Group, Tiziana Life Sciences, Cava, Lowe’s… - Proactive Investors
Tiziana reports biomarker gains for nasal MS therapy in progressive disease - Yahoo
Tiziana Life Sciences PLC (TLSA) announces new biomarker data - Bitget
Tiziana Life Sciences Posts Positive Biomarker Data for Intranasal Foralumab in Progressive MS - TipRanks
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA - The Manila Times
New foralumab biomarker data in na-SPMS from Tiziana (Nasdaq: TLSA) - Stock Titan
Tiziana Life Sciences Ltd. - Via Ritzau
What’s next for Tiziana Life Sciences Ltd stockIndex Update & Safe Capital Growth Stock Tips - mfd.ru
Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 0.7%Here's What Happened - MarketBeat
Does Tiziana Life Sciences Ltd outperform in volatile markets2025 Growth vs Value & Short-Term Trading Alerts - mfd.ru
What is Tiziana Life Sciences Ltd s 5 year growth outlookM&A Rumor & Smart Allocation Stock Reports - mfd.ru
TLSA PE Ratio & Valuation, Is TLSA Overvalued - Intellectia AI
TLSA Should I Buy - Intellectia AI
Is Tiziana Life Sciences Ltd stock affected by interest rate hikesPortfolio Value Report & Risk Adjusted Buy and Sell Alerts - mfd.ru
How Tiziana Life Sciences Ltd stock reacts to Fed rate cutsWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - mfd.ru
Is Tiziana Life Sciences Ltd in a consolidation phaseEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru
Can Tiziana Life Sciences Ltd sustain earnings growth2025 Trade Ideas & Safe Capital Growth Stock Tips - mfd.ru
Tiziana Life Sciences Ltd Stock (TLSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):